Fundraising Fox
/Companies
Sign in

Cellphire

Rockville, US · Founded 2005 · Delaware corporation · 48 employees on LinkedIn · 2 known investors

Find your way into Cellphire

Each arrow is one introduction. Sign up to fill in the first one.

715 people can intro you to Michael

Ask Mike Dowdle to introduce you to Michael Gaffney

You →Mike · together at Cellphire →Michael

Sign up to find every way you can get introduced to Cellphire

  • Your email: who you already know at Cellphire, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Cellphire team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Cellphire Therapeutics develops platelet-based and freeze-dried cellular therapeutics for transfusion medicine, focused on controlling hemorrhage. Through its veterinary subsidiary BodeVet, it also markets freeze-dried platelet products for companion and exotic animals.

BiotechMedical Devices

Founders & leadership

MGMichael Gaffney
Michael GaffneyChief Executive OfficerMichael Gaffney is an executive with background in private equity and healthcare services, including health insurance, healthcare IT, and outsourced services. He holds a BS from the US Naval Academy and an MA from Oxford University, and previously served as a nuclear submarine officer.
DH
David HirshNamed on SEC filing
CW
Cristiane WolfeNamed on SEC filing
AH
Angela HowertonNamed on SEC filing
RW
Rob WoodsNamed on SEC filing

Board

PC
Pamela ConleyBoard director
RJ
Rafael JordaBoard Director
TD
Thomas DubinBoard director
DW
Derek WoodsBoard director
RSRandall Stanicky
Randall StanickyBoard Member
JP
James PeakeBoard director

Investors · 2

Manta Ray Ventureslisted by Manta Ray VenturesLondon

How we know: Manta Ray Ventures's portfolio page · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$5M disclosed across 2 rounds · 2023–2025

▶$3MraisedDec 2025 · 19 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Pamela ConleyDirector
  • Rafael JordaDirector
  • Thomas DubinDirector
  • Michael GaffneyExecutive Officer, Director
  • Derek WoodsDirector
  • Randall StanickyDirector
  • James PeakeDirector
Offering amount
$3M
Amount sold
$3M
Minimum investment
$17.7K
First sale
Nov 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedOct 2023 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David HirshDirector
  • Cristiane WolfeExecutive Officer
  • Michael GaffneyExecutive Officer, Director
  • Rafael JordaDirector
  • Derek WoodsDirector
  • James PeakeDirector
  • Thomas DubinDirector
  • Angela HowertonExecutive Officer
  • Pamela ConleyDirector
  • Rob WoodsExecutive Officer
Offering amount
$8M
Amount sold
$2M
Minimum investment
$100K
First sale
Sep 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 3

Spyre TherapeuticsSpyre develops and commercializes treatments for a broad range of diseases focused on improving patient outcomes.
Click TherapeuticsClick Therapeutics develops, validates, and commercializes software-based prescription medical treatments, including software-enhanced drug products that combine digital therapeutics with pharmacotherapy. It targets diseases through a platform-based approach applying neuroscience and neuromodulatory mechanisms for patients with unmet medical needs.
Kite PharmaKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.

Companies working in the same space as Cellphire.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
Department of DefenseSpecial Operations CommandPhase I2017$149.6K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Cellphire do?
Cellphire Therapeutics develops platelet-based and freeze-dried cellular therapeutics for transfusion medicine, focused on controlling hemorrhage. Through its veterinary subsidiary BodeVet, it also markets freeze-dried platelet products for companion and exotic animals.
Who are Cellphire's investors?
Cellphire's investors include Circadian Ventures, Manta Ray Ventures.
How much funding has Cellphire raised?
Cellphire has disclosed $5M raised across 2 rounds.
Where is Cellphire headquartered?
Cellphire is headquartered in Rockville, US.